Wells Fargo
PHAT icon

Wells Fargo’s Phathom Pharmaceuticals PHAT Stock Holding History

Wells Fargo’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$512K Sell
46,113
-21,903
-32% -$277K ﹤0.01% 4152
2025
Q4 		$1.13M Buy
68,016
+14,368
+27% +$205K ﹤0.01% 3874
2025
Q3 		$631K Buy
53,648
+6,970
+15% +$71.9K ﹤0.01% 4129
2025
Q2 		$448K Buy
46,678
+18,253
+64% +$101K ﹤0.01% 4235
2025
Q1 		$178K Buy
28,425
+2,909
+11% +$17.7K ﹤0.01% 4789
2024
Q4 		$207K Buy
25,516
+7,462
+41% +$92.4K ﹤0.01% 4778
2024
Q3 		$326K Buy
18,054
+739
+4% +$10.3K ﹤0.01% 4274
2024
Q2 		$178K Buy
17,315
+5,710
+49% +$58.8K ﹤0.01% 4589
2024
Q1 		$123K Buy
11,605
+715
+7% +$6.07K ﹤0.01% 4776
2023
Q4 		$99.4K Buy
10,890
+3,616
+50% +$31.2K ﹤0.01% 4900
2023
Q3 		$75.4K Sell
7,274
-2,324
-24% -$31.9K ﹤0.01% 4947
2023
Q2 		$137K Buy
9,598
+4,872
+103% +$56.2K ﹤0.01% 4824
2023
Q1 		$33.7K Buy
+4,726
New +$41.5K ﹤0.01% 5382
2022
Q4 		– Sell
-407
Closed -$5K – 7648
2022
Q3 		$5K Sell
407
-192
-32% -$1.83K ﹤0.01% 5917
2022
Q2 		$5K Sell
599
-1,006
-63% -$10.3K ﹤0.01% 6018
2022
Q1 		$22K Sell
1,605
-7,188
-82% -$116K ﹤0.01% 5979
2021
Q4 		$173K Buy
+8,793
New +$207K ﹤0.01% 5348
2021
Q2 		– Sell
-3,527
Closed -$132K – 7300
2021
Q1 		$132K Sell
3,527
-7,762
-69% -$325K ﹤0.01% 5353
2020
Q4 		$375K Buy
11,289
+2,662
+31% +$108K ﹤0.01% 4734
2020
Q3 		$316K Sell
8,627
-2,880
-25% -$99.7K ﹤0.01% 4678
2020
Q2 		$379K Buy
11,507
+5,208
+83% +$200K ﹤0.01% 4521
2020
Q1 		$163K Buy
6,299
+5,423
+619% +$181K ﹤0.01% 4805
2019
Q4 		$27K Buy
+876
New +$22K ﹤0.01% 5672

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Wells Fargo's PHAT Position: Q1 2026 in Review

Wells Fargo reduced its Phathom Pharmaceuticals (PHAT) stake by 32% in Q1 2026, selling an estimated $277K and leaving 46,113 shares worth $512K. The position accounts for ﹤0.01% of the portfolio, ranked #4152.

Wells Fargo first reported a position in PHAT in Q4 2019 and has held it in 23 quarters since. The position peaked at $1.13M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Wells Fargo held 46,113 shares of Phathom Pharmaceuticals worth $512K as of Q1 2026.
  • Wells Fargo sold 21,903 Phathom Pharmaceuticals shares in Q1 2026, an estimated $277K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4152 holding.
  • Wells Fargo first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • Wells Fargo's Phathom Pharmaceuticals position peaked at $1.13M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.